复方苦参注射液联合新辅助化疗对乳腺癌患者免疫功能的影响  

Effect of Compound Kushen Injection Combined with Neoadjuvant Chemotherapy on Immune Function of Breast Cancer

作　　者：吴海滨[1] 马志强[1] 湛喜梅 李帅[1] 苗雅云 张冠男[1] 王文胜[1] WU Haibin;MA Zhiqiang;ZHAN Ximei;LI Shuai;MIAO Yayun;ZHANG Guannan;WANG Wensheng(Department of Breast and Thyroid Surgery,The First Affiliated Hospital of Henan University,Henan Province,Kaifeng 475100,China)

机构地区：[1]河南大学第一附属医院乳腺甲状腺外科,河南开封475100

出　　处：《光明中医》2023年第19期3816-3819,共4页GUANGMING JOURNAL OF CHINESE MEDICINE

基　　金：河南省开封市科技发展计划(No.2203028)。

摘　　要：目的 探究复方苦参注射液(CKI)联合新辅助化疗对乳腺癌患者免疫功能的改善作用。方法 选取2021年4月—2022年4月医院收治的乳腺癌患者96例,按照随机数字表法分为2组,对照组(48例)给予新辅助化疗,研究组(48例)给予CKI联合新辅助化疗。比较近期疗效、血清肿瘤标志物表达、免疫功能、不良反应,同时检测癌组织中Survivin、细胞核增殖抗原(k_(i)-67)蛋白表达。结果 研究组客观缓解率(ORR)高于对照组(P<0.05),疾病控制率(DCR)较对照组高,差异无统计学意义(P>0.05),不良反应发生率均低于对照组(P<0.05)。治疗后,2组的癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原153(CA153)、Survivin(+)构成比、ki-67(+)构成比低于治疗前(P<0.05),且研究组低于对照组(P<0.05)。治疗后,对照组的CD4^(+)、CD3^(+)、CD4^(+)/CD8^(+)低于治疗前(P<0.05),研究组的CD4^(+)、CD3^(+)、CD4^(+)/CD8^(+)高于治疗前(P<0.05),且研究组的CD4^(+)、CD3^(+)、CD4^(+)/CD8^(+)高于对照组(P<0.05)。结论 CKI联合新辅助化疗能改善乳腺癌患者的免疫功能,下调血清肿瘤标志物与癌组织中Survivin(+)、ki-67(+)蛋白表达,提高近期疗效,且不良反应少。Objective To explore the improvement effect of compound Kushen Injection(CKI) combined with neoadjuvant chemotherapy on the immune function of breast cancer patients.Methods Ninety-six patients with breast cancer admitted to the hospital from April 2021 to April 2022 were selected and divided into two groups according to the random number table.The control group of 48 cases was given neoadjuvant chemotherapy,and the study group of 48 cases was given CKI combined with neoadjuvant chemotherapy.The short-term curative effect,the expression of serum tumor markers,immune function and adverse reactions were compared,and the expression of survivin and ki-67 proteins in cancer tissues were detected.Results The objective response rate(ORR) of the study group was higher than that of the control group(P<0.05),and the disease control rate(DCR) of the study group was higher than that of the control group,with no statistical significance(P<0.05),and the incidence of adverse reactions was lower than that of the control group(P>0.05).After treatment,CEA,carbohydrate antigen 125(CA125),carbohydrate antigen 153(CA153),Survivin(+) component ratio and ki-67(+) component ratio in 2 groups were lower than before treatment(P<0.05),and the study group was lower than the control group(P<0.05).After treatment,CD4^(+),CD3^(+),CD4^(+)/CD8^(+) in the control group were lower than before treatment(P<0.05),CD4^(+),CD3^(+),CD4^(+)/CD8^(+) in the study group were higher than before treatment(P<0.05),and CD4^(+),CD3^(+),CD4^(+)/CD8^(+) in the study group were higher than those in the control group(P<0.05).Conclusion CKI combined with neoadjuvant chemotherapy can improve the immune function of breast cancer patients,reduce the expression of tumor markers in serum,and survivin(+) and ki-67(+) proteins in cancer tissues,improve the short-term efficacy,and have fewer adverse reactions.

关 键 词：乳岩 乳腺癌 复方苦参注射液 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤]